Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction

Area of Science:

• Hepatology
• Cardiology
• Metabolic Disorders

Background:

• Obesity is a primary driver of nonalcoholic fatty liver disease (NAFLD) progression to nonalcoholic steatohepatitis (NASH).
• NAFLD significantly elevates cardiovascular disease (CVD) risk in affected patients.

Purpose of the Study:

• To elucidate the impact of obesity on NASH development and progression.
• To detail the cascading effects of obesity-induced NASH on cardiovascular dysfunction.
• To review current and emerging therapeutic strategies for NASH.

Main Methods:

• Literature review summarizing epidemiological and pathophysiological links between obesity, NASH, and cardiovascular dysfunction.
• Analysis of recent studies on NASH and cardiac comorbidities.
• Evaluation of treatment options, including lifestyle interventions, pharmacotherapy, and surgical approaches.

Main Results:

• Obesity critically influences NASH pathogenesis and contributes to endothelial and diastolic cardiac dysfunction, alongside increased coronary artery calcification.
• Lifestyle modifications (diet, exercise, behavioral therapy) improve both NASH and cardiovascular outcomes.
• Vitamin E and pioglitazone are recommended for biopsy-proven NASH, with several other agents (NGM282, obeticholic acid, elafibranor, liraglutide) under investigation.
• Bariatric surgery demonstrates significant efficacy in resolving NASH.

Conclusions:

• Obesity is intrinsically linked to NASH and subsequent cardiovascular complications.
• Comprehensive management strategies, including lifestyle changes and targeted therapies, are crucial for addressing NASH and its associated cardiac risks.
• Emerging treatments and bariatric surgery offer promising avenues for NASH management.